This database contains 523 studies, archived under the term: "Alzheimer’s Disease"
Click here to filter this large number of results.
Safety and tolerability of rivastigmine capsule with memantine in patients with probable Alzheimer’s disease: a 26-week, open-label, prospective trial (Study ENA713B US32)
Olin, Jason T.,
Bhatnagar, Vinod,
Reyes, Patricio,
Koumaras, Barbara,
Meng, Xiangyi,
Brannan, Stephen
Objective: Rivastigmine, a dual cholinesterase inhibitor (ChEI), is widely approved for the symptomatic treatment of both mild-to-moderate Alzheimer’s disease (AD) and Parkinson’s disease dementia. Orally administered ChEIs may be associated with gastrointestinal (GI) side effects and add-on therapy with memantine, an N-methyl-d-aspartate receptor antagonist, approved for moderate-to-severe AD, may ameliorate such side effects. This was […]
Urine neural thread protein measurements in Alzheimer disease
Objectives: Neural thread protein (NTP), a membrane-associated phosphoprotein, was selectively elevated in the urine of patients with Alzheimer disease (AD). To demonstrate the potential utility of urine NTP assays for the diagnosis of AD, we performed this study.; Design: A prospective blinded multicentered study.; Participants: Individuals diagnosed as having probable AD (n = 49), Parkinson’s […]
Visual evoked potentials to pattern, motion and cognitive stimuli in Alzheimer’s disease
Kubová, Z.,
Kremlácek, J.,
Valis, M.,
Langrová, J.,
Szanyi, J.,
Vít, F.,
Kuba, M.
The aim of our study was to verify reported visual dysfunctions of patients with Alzheimer disease with the use of several variants of VEPs and visual ERPs and to learn whether these methods can be useful in diagnostics of AD. We tested 15 patients (6 women and 9 men, aged from 58 to 87) with […]
Errorless practice as a possible adjuvant to donepezil in Alzheimer’s disease
Rothi, Leslie J. Gonzalez,
Fuller, Renee,
Leon, Susan A.,
Kendall, Diane,
Moore, Anna,
Wu, Samuel S.,
Crosson, Bruce,
Heilman, Kenneth M.,
Nadeau, Stephen E.
Six individuals with probable Alzheimer’s disease (AD) participated in a phase 1 study employing a repeated measures, parallel baseline design testing the hypothesis that error-free experience during word production practice combined with an acetyl cholinesterase inhibitor would improve confrontation naming ability. While acetyl cholinesterase inhibitors are safe and delay cognition decline associated with AD, improvement […]
Long-term safety and efficacy of donepezil in patients with severe Alzheimer’s disease: results from a 52-week, open-label, multicenter, extension study in Japan
Homma, Akira,
Imai, Yukimichi,
Tago, Hisao,
Asada, Takashi,
Shigeta, Masahiro,
Iwamoto, Toshihiko,
Takita, Masashi,
Arimoto, Itaru,
Koma, Hiroshi,
Takase, Takao,
Ohbayashi, Toshio
Background/aims: A 6-month, randomized, double-blind, placebo-controlled study was extended to evaluate long-term safety and efficacy of donepezil in community-dwelling Japanese patients with severe Alzheimer’s disease (AD).; Methods: 189 patients were enrolled from the double-blind study into a 52-week, open-label extension study. After a 2- to 8-week washout, donepezil was escalated within 6 weeks to 10 […]
Lithium trial in Alzheimer’s disease: a randomized, single-blind, placebo-controlled, multicenter 10-week study
Hampel, Harald,
Ewers, Michael,
Bürger, Katharina,
Annas, Peter,
Mörtberg, Anette,
Bogstedt, Anna,
Frölich, Lutz,
Schröder, Johannes,
Schönknecht, Peter,
Riepe, Matthias W.,
Kraft, Inga,
Gasser, Thomas,
Leyhe, Thomas,
Möller, Hans-Jürgen,
Kurz, Alexander,
Basun, Hans
Objective: Lithium, a first-line drug for the treatment of bipolar depression, has recently been shown to regulate glycogen synthase kinase-3 (GSK-3), a kinase that is involved in the phosphorylation of the tau protein. Since hyperphosphorylation of tau is a core pathological feature in Alzheimer’s disease, lithium-induced inhibition of GSK-3 activity may have therapeutic effects in […]
Long-term follow-up of patients immunized with AN1792: reduced functional decline in antibody responders
Vellas, Bruno,
Black, R.,
Thal, Leon J.,
Fox, Nick C.,
Daniels, M.,
McLennan, G.,
Tompkins, C.,
Leibman, C.,
Pomfret, M.,
Grundman, Michael
Background: Immunization of patients with Alzheimer’s disease (AD) with synthetic amyloid-beta peptide (Abeta(42)) (AN1792) was previously studied in a randomized, double-blind, placebo-controlled phase 2a clinical trial, Study AN1792(QS-21)-201. Treatment was discontinued following reports of encephalitis. One year follow-up revealed that AN1792 antibody responders showed improvements in cognitive measures as assessed by the neuropsychological test battery […]
Effect of tramiprosate in patients with mild-to-moderate Alzheimer’s disease: exploratory analyses of the MRI sub-group of the Alphase study
Gauthier, S.,
Aisen, P. S.,
Ferris, S. H.,
Saumier, D.,
Duong, A.,
Haine, D.,
Garceau, D.,
Suhy, J.,
Oh, J.,
Lau, W.,
Sampalis, J.
Objectives: The efficacy, safety and disease-modification of tramiprosate (homotaurine)were investigated in a recently completed large-scale Phase III clinical study in patients with mild to moderate Alzheimer’s disease (AD), the Alphase study. Disease-modification was assessed using longitudinal volumetric MRI (vMRI) measurements of the hippocampus in a subgroup of patients. The present study describes the vMRI, cognitive […]
Ginkgo biloba extract EGb 761(R), donepezil or both combined in the treatment of Alzheimer’s disease with neuropsychiatric features: a randomised, double-blind, exploratory trial
Yancheva, S.,
Ihl, R.,
Nikolova, G.,
Panayotov, P.,
Schlaefke, S.,
Hoerr, R.
Objective: This randomised, double-blind exploratory trial was undertaken to compare treatment effects and tolerability of EGb 761(R), donepezil and combined treatment in patients with AD and neuropsychiatric features.; Method: We enrolled 96 outpatients, aged 50 years or above, who met the NINCDS/ADRDA criteria for probable AD, scored below 36 on the TE4D, a screening test […]